TD Cowen downgraded Inozyme (INZY) to Hold from Buy with a $4 price target after BioMarin Pharmaceutical (BMRN) agreed to acquire the company for $4.00 per share in cash.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INZY:
- Inozyme Pharma’s Strategic Acquisition by Biomarin: Analyst Holds Rating Amid Favorable Shareholder Outcome and Strategic Alignment
- Inozyme downgraded to Neutral from Overweight at Piper Sandler
- Inozyme downgraded to Hold from Buy at Jefferies
- Leerink bullish on BioMarin following Inozyme deal, expects additional BD
- Inozyme downgraded to Market Perform from Outperform at Raymond James